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Abstract
Background The knowledge in the field of castration-resistant prostate cancer (CRPC) is developing rapidly, with emerging 
new therapies and advances in imaging. Nonetheless, in multiple areas there is still a lack of or very limited evidence, and 
clear guidance from clinicians regarding optimal strategy is required.
Methods A modified Delphi method, with 116 relevant questions divided into 7 different CRPC management topics, was 
used to develop a consensus statement by the URONCOR group.
Results A strong consensus or unanimity was reached on 93% of the proposed questions. The seven topics addressed were: 
CRPC definition, symptomatic patients, diagnosis of metastasis, CRPC progression, M0 management, M1 management and 
sequencing therapy, and treatment monitoring.
Conclusions The recommendations based on the radiation oncology experts’ opinions are intended to provide cancer special-
ists with expert guidance and to standardise CRPC patient management in Spain, facilitating decision-making in different 
clinically relevant issues regarding CRPC patients.
Keywords Castration-resistant prostate cancer · Radiation oncology · Consensus · Delphi · Management · Metastasic · 
Therapeutics · Oligometastasic prostate cancer
Introduction
Prostate cancer is the second most common cancer in men 
worldwide. In recent years, in Europe as in Spain, it has 
been the most frequent (360,000 cases diagnosed in the 
EU-27 in 2012 and 33,370 new cases in Spain in 2015) [1], 
with the incidence presenting a significant increase after the 
fifth decade. In 2012 it was the malignancy with the high-
est incidence and prevalence in Spain (12.9%) [2, 3]. Data 
from population-based cancer registries in Spain have shown 
an improvement in prostate cancer prognosis, with 84.5% 
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5-year relative survival (95% CI 83.6–85.6%) [4]. However, 
this survival rate drops rapidly among the older age patients 
with an advanced stage of the disease at diagnosis [5].
Although most patients initially respond to medical radia-
tion or surgical therapy, around 10–20% of prostate can-
cer patients develop a castration-resistant prostate cancer 
(CRPC), within 5 years of follow-up [6]. CRPC is a het-
erogeneous disease, with metastases present in over 84% of 
patients [7], deterioration in the quality of life and shorter 
survival compared with castration-sensitive patients [6, 8].
Treatment for CRPC has improved considerably in these 
recent years, with several agents extending life, includ-
ing androgen-receptor pathway therapies (enzalutamide, 
abiraterone) [9, 10], autologous cellular immunotherapy 
(sipuleucel-T, not available in Europe) [11], radium-223 
[12] and cabazitaxel [13]. Despite these new emerging 
therapies, there is an absence of face-to-face comparative 
studies between therapeutic options. Therefore, there is still 
controversy on how to sequence or combine these therapies 
in order to provide the greatest benefits to the patients [14].
Furthermore, with the availability of new imaging tools 
the diagnoses of metastasis and progression in CPRC is 
constantly evolving and there are no clear recommenda-
tions on when to initiate imaging or the testing frequency in 
clinical practice. The usefulness of new imaging technique 
in advanced prostate cancer and its clinical benefit will be 
answered in trials that directly assess these techniques.
To address this issue, the SEOR Urological Tumour 
Working Group (URONCOR) consulted a working panel 
of 25 radiation oncologist experts in order to provide a con-
sensus on many controversial aspects in CRPC management, 
including the definition of CRPC, aspects relating to symp-
tomatic patients, diagnosis of metastasis, CRPC progres-
sion, M0 management, M1 management and sequencing 
therapy, and the monitoring of treatment. The conclusions 
were used to generate a document intended to standardise 
CRPC patient management and to facilitate decision-making 
in this stage across Spain.
Materials and methods
The consultation process followed a modified Delphi 
method. In the first phase, a scientific committee with 4 
radiation oncologists plus a coordinator (supplementary 
data) identified several critical controversial areas in CRPC 
and developed a questionnaire covering 7 topics with a total 
of 116 questions. In the second phase, URONCOR sent 
the questionnaire to a working panel of 25 experts (sup-
plementary data) to obtain their opinions on best practice. 
The questions were answered in two separate rounds and a 
face-to-face meeting, where panelists were able to discuss 
their answers and to vote again on any conflicting items 
through an anonymous televoting system (9–10 February 
2017, Madrid, Spain).
Questions that resulted in an absolute consensus (100%) 
were classified as having unanimity, 80% or more was clas-
sified as a strong consensus, 70–79% represented a moderate 
consensus and 29–69% was defined as having no consensus. 
Issues that reached a moderate consensus or had no con-
sensus in the second round were debated in the face-to-face 
meeting.
Results
The questionnaire covered a total of 116 clinically relevant 
issues categorised under 7 controversial areas relating to 
CRPC and its treatment: CRPC definition, (Topic 1), Symp-
tomatic patients (Topic 2), Diagnosis of metastasis (Topic 
3), CRPC progression (Topic 4), M0 management (Topic 
5), M1 management and sequencing therapy (including 
metastasis monitoring; Topic 6) and Monitoring of response 
(Topic 7).
After the two rounds and the face-to-face meeting, a con-
sensus was reached on 108 of the 116 questions (93%), with 
unanimity on 22 items (19.0%) and a strong consensus on 86 
questions (74.1%). Three questions (2.6%) reached a mod-
erate consensus while the remaining five questions had no 
consensus (4.3%) (Figs. 1 and 2, Table 1).
Table 2 shows the voting results of the expert panel 
obtained by the Urological Tumours Working Group 





Strong consensus Unanimity Moderate consensus No consensus
Fig. 1  Consensus after the face-to-face session (percentage)
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Consensus development and panel discussion
Topic 1—CRPC definition
Several definitions of CRPC have been proposed over time. 
Similarly, the diagnostic criteria used in clinical studies have 
been extremely heterogeneous [6]. Recently, the European 
Expert Consensus Panel [15] defined CRPC patients as men 
with castrate serum testosterone levels and confirmed PSA 
progression. Spanish urologist experts added radiological 
progression to the definition of CRPC [16]. The St Gallen 
expert group considered that a confirmed rising PSA is suf-
ficient to diagnose CRPC in patients on ADT with castrate 
levels of testosterone [17].
The panel strongly agreed (96%) that CRPC was defined 
by a documented rising PSA (≥ 2 ng/ml) and/or radiologi-
cal progression in men with testosterone levels of < 50 ng/dl 
(< 1.7 nmol/l). In addition, they strongly agreed (88%) that 
a rising PSA after the use of 2 or more hormonal therapies 
was not required to define CRPC.
Topic 2—Symptomatic patients
In the TAX327 trial, pain response was found to be a prog-
nostic end-point for overall survival, even if it did not meet 
strict surrogacy criteria [18]. There is a degree of uncer-
tainty among the end-point criteria on whether to consider 
an asymptomatic/minimally symptomatic patient in clinical 
trials [11, 19]. The URONCOR consensus statement agreed 
to define these patients as those with bone metastasis with-
out pain or mild/moderate pain controlled with first- or sec-
ond-line WHO pain scale analgesics [20], or patients who 
have shown a good analgesic response to palliative RT and/
or to bisphosphonates [21]. In addition, different publica-
tions support the use of symptom assessment tools to evalu-
ate pain in CRPC [22–24].
The panel agreed that a minimally symptomatic CRPC 
patient was defined as having a low score in validated pain 
scales (100%) and showing a response to non-steroidal anti-
inflammatory drugs (NSAID) (100%). A strong consensus 
was reached on previous response to antialgic radiotherapy 
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Fig. 2  Results by topic (percentage) of the consensus after the face-to-face session
Table 1  Results of the 
consensus reached after 
the face-to-face session by 
topic (number of questions, 
percentage)
N Unanimity Strong consensus Consensus No Consensus
N (%) N (%) N (%) N (%)
Topic 1—CRPC definition 2 100.0%
Topic 2—Symptomatic patients 8 25.0% 62.5% 12.5%
Topic 3—Diagnosis of metastasis 30 3.3% 96.7%
Topic 4—CRPC progression 21 23.8% 66.7% 9.5%
Topic 5—M0 management 6 50.0% 50.0%
Topic 6—M1 management and 
sequencing therapy
29 24.1% 62.1% 3.5% 10.3%
Topic 7—Treatment monitoring 20 20.0% 75.0% 5.0%
116 22 (19%) 86 (74.1%) 3 (2.6%) 5 (4.3%)
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Table 2  Consensus panel voting results on CRPC from the Urological Tumour Working Group (URONCOR) of the Spanish Society of Radia-
tion Oncology
Yes No Consensus level
Topic 1—CRPC definition
 In patients with castrate levels of testosterone, CRPC can be defined as:
  Confirmed PSA progression (> 2 ng/ml) and/or radiological progression 96% 4% SC




 Criteria to define a minimally symptomatic patient
  Low score on validated pain scales 100% 0% U
  Pain response to NSAID/paracetamol 100% 0% U
  Pain control by opioids 12% 88% SC
  Previous response to antalgic radiotherapy 80% 20% SC
 Scales used to assess the patient’s pain:
  BPI–SF (Brief Pain Inventory – Short Form) 92% 8% SC
  Visual analogic scale 96% 4% SC
  Subjective patient assessment/verbal scales 28% 72% MC
  Scales are not important in evaluating patient pain 4% 96% SC
Topic 3—Diagnosis of metastasis
 Bone scan (BS)
 In a CPRC patient, a BS would be appropriate to perform in the following scenarios:
  At CRPC diagnosis, regardless of PSA levels 88% 12% SC
  When PSA level is > 10 ng/ml and/or PSA-DT at < 6 months 92% 8% SC
  At the onset of bone pain 92% 8% SC
 Given a negative BS in an asymptomatic M0 CRPC patient, the test would be repeated under the following circumstances:
  PSA level of > 10 ng/ml and/or PSA-DT at < 6 months 92% 8% SC
  PSA level of > 2 ng/ml and/or PSA-DT at 6–12 months 16% 84% SC
  Every 3–6 months regardless of PSA values 20% 80% SC
  Exclusively with the onset of pain 16% 84% SC
 In a CPRC patient with bone pain, in the event of a negative/inconsistent BS:
  Wait to know what the PSA kinetics are 12% 88% SC
  An additional imaging test is required (standard x-rays of areas of concern, axial skeleton 
MRI scan, CT bone scan or choline PET/CT)
92% 8% SC
CT Scan
 In a CPRC patient, a chest, abdomen and pelvis CT scan would be appropriate to perform:
  At CRPC diagnosis, regardless of PSA levels 96% 4% SC
  With a PSA level of > 10 ng/ml and/or PSA-DT at < 6 months 88% 12% SC
  At the onset of metastatic related symptoms 96% 4% SC
 In a CPRC M0 asymptomatic patient, with a negative CT scan, the following test should be repeated:
  With a PSA level of > 10 ng/ml and/or PSA-DT at < 6 months 96% 4% SC
  With a PSA level of > 2 ng/ml and/or PSA-DT at 6–12 months 16% 84% SC
  Every 3–6 months regardless of PSA values 16% 84% SC
  Only if they present symptoms 16% 84% SC
 In a symptomatic CPRC patient, in the event of a negative/inconsistent CT Scan:
  Wait to know what the PSA kinetics are 12% 88% SC
  An additional imaging test is required (whole-body MRI or choline PET/CT) 100% 0% U
Choline PET/CT/Whole-body MRI
 Performing PET/CT would be appropriate for CRPC patients:
  In order to confirm inconclusive M1 test results 88% 12% SC
  Following a negative conventional cancer staging study (CT and BS) 12% 88% SC
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Table 2  (continued)
Yes No Consensus level
  Following a negative conventional cancer staging study (CT and BS) and aggressive PSA 
kinetics
96% 4% SC
 Performing a whole-body MRI would be the best option for CRPC patients:
  In order to confirm inconclusive M1 test results 100% 0% U
  Following a negative conventional cancer staging study (CT and BS) 20% 80% SC





  Lack of visceral disease 8% 92% SC
  Ganglionic and/or bone disease (5 areas or fewer) 92% 8% SC
 Images needed in order to diagnose the oligometastatic CPRC patient:
  CT and BS 84% 16% SC
  Choline PET/CT 88% 12% SC
  Whole-body MRI 80% 20% SC
 Do you agree with the following statement?




 Do you agree that the following statements define the progression of a CPRC patient?
  Exclusive biochemical progression 12% 88% SC
  Radiological progression 96% 4% SC
  Clinical progression (pain, overall status) 88% 12% SC
 Which statements define primary resistance to therapies targeting the androgen receptor pathway (enzalutamide/abiraterone):
  Absence of decline in PSA level (≥ 30%) during the first 3 months 12% 88% SC
  Sustained PSA progression within 3–4 months of therapy initiation 68% 32% NC
  Radiological progression within 3–4 months of therapy initiation 92% 8% SC
 Statements related to the flare-up occurrence
  A flare-up is defined as a temporary clinical and/or biochemical worsening since therapy 
initiation
92% 8% SC
  A flare-up occurs with taxane treatment 100% 0% U
  A flare-up occurs with enzalutamide treatment 56% 44% NC
  A flare-up occurs with abiraterone treatment 100% 0% U
 The following parameters are predictive factors of poor response to therapies:
  High primary tumour Gleason score 100% 0% U
  Short response duration after first-line hormonal therapy (LHRH) 96% 4% SC
  Presence of visceral metastasis 100% 0% U
  Short PSA-DT 96% 4% SC
  High LDH and/or alkaline phosphatase 92% 8% SC
  Moderate to severe pain score 92% 8% SC
  Overall poor condition (ECOG performance status) 100% 0% U
 The following parameters are prognostic factors of disease progression:
  Presence of circulating tumour cells (≥ 5/7.5 ml) 84% 16% SC
  Presence of androgen receptor splice variant (AR-V7) 92% 8% SC
 Do you agree with the following definition of the biochemical progression of the CPRC patient?
  Three consecutive PSA increases one week apart, resulting in two 50% increases over the 
nadir and a PSA level of > 2 ng/ml
88% 12% SC
  Three consecutive PSA increases one week apart, resulting in two 50% increases over the 
nadir and a PSA level of > 1 ng/ml
12% 88% SC
425Clinical and Translational Oncology (2019) 21:420–432 
1 3
Table 2  (continued)
Yes No Consensus level
Topic 5—M0 management
 In an M0 CRPC patient, do you agree with the following statements?
  An initial BS should be requested for PSA levels of > 2 ng/ml 84% 16% SC
  For PSA levels of > 2 ng/ml and negative BS, the test should be repeated when PSA levels 
reach ≥ 5 ng/ml
88% 12% SC
  For PSA levels of ≥ 5 ng/ml and negative BS, the test should be repeated each time the 
PSA level doubles and PSA should be tested every 3 months
88% 12% SC
 In an M0 CRPC patient with local clinical progression, the first-line therapy would be:
  Radiotherapy (if no prior RT) or salvage surgery 100% 0% U
  Docetaxel 0% 100% U
  New antiandrogen therapies (enzalutamide/abiraterone) 0% 100% U
Topic 6—M1 management and sequencing therapy
 In an asymptomatic/minimally symptomatic M1 CRPC patient the first-line therapy would be:
  Enzalutamide/abiraterone in most cases 100% 0% U
  Docetaxel in most cases 0% 100% U
  Docetaxel in some aggressive cases 92% 8% SC
 In an initially asymptomatic or minimally symptomatic M1 CRPC patient, the following factors would influence the choice of treatment:
  Visceral metastases 96% 4% SC
  Hypertension 44% 56% NC
  History of cardiovascular disease 72% 28% MC
  History of seizures 80% 20% SC
  Contradindications for steroid use 96% 4% SC
 In an asymptomatic/minimally symptomatic M1 CRPC patient with visceral metastasis, first-line therapy would be:
  Enzalutamide 80% 20% SC
  Abiraterone 0% 100% U
  Docetaxel 20% 80% SC
 In an asymptomatic/minimally symptomatic M1 CRPC patient, secondary hormonal manipulations
  Are suitable for patients who are not candidates for chemotherapy only when enzaluta-
mide/abiraterone are not available
88% 12% SC
  Are suitable for patients who are not candidates for chemotherapy regardless of enzaluta-
mide/abiraterone availability
0% 100% U
  Are suitable for all patients, regardless of whether they are chemotherapy candidates or 
not
4% 96% SC
 If there is progression…
  A biopsy of the metastatic lesion would be performed to check for a change in the tumour 
phenotype.
52% 48% NC
 In a symptomatic M1 CRPC patient the first-line therapy would be:
  New antiandrogenic drugs (enzalutamide/abiraterone) 16% 84% SC
  Docetaxel 84% 16% SC
  Radium-223 (in bone/non-visceral metastases) 92% 8% SC
 Do you agree with the following statement?
  Most CPRC with symptomatic bone metastases should be treated with bone-targeting 
therapies (bisphosphonate, denosumab, if there areno contraindications).
88% 12% SC
 If you answered yes to the previous question, the bone-targeting therapies must be continued:
  For 12–24 months 55% 45% NC
  Until the onset of bone progression 82% 18% SC
 The local control of oligometastasis…
  Decreases symptoms. 92% 8% SC
  Delays the start of a new systemic treatment 88% 12% SC
  Increases overall/progression-free survival 84% 16% SC
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in the definition of CRPC (88%). The panel also strongly 
agreed that the BPI-SF (Brief Pain Inventory-Short Form) 
(92%) and a visual analogic scale (96%) should be used to 
assess patient pain.
Topic 3—Diagnosis of metastasis
There is no agreed definition on what constitutes the stand-
ard of care for detection of metastatic disease in CRPC. The 
EAU-ESTRO-SIOG guidelines [25] stated that in men with 
Table 2  (continued)
Yes No Consensus level
 In oligometastatic CPRC patients…
  Local ablative therapy in addition to the new antiandrogenic drugs (enzalutamide/abira-
terone) must be considered
92% 8% SC
  A radical prostate treatment should be performed 100% 0% U
 In the CPRC patient the following supportive therapies must be offered:
  Calcium and vitamin D when denosumab or bisphosphonates are prescribed 96% 4% SC
  External radiotherapy, radiopharmaceuticals and analgesia in cases of painful bone metas-
tases
100% 0% U




 Imaging test suitable to evaluate bone metastasis response to the therapy
  Tc-99 m bone scan 84% 16% SC
  Whole body MRI and/or axial skeleton 92% 8% SC
  Choline PET/TC 84% 16% SC
 In an asymptomatic/minimally symptomatic CPRC patient, does the first-line therapy choice influence the frequency of patient monitoring in 
the following?
  Follow-up patient visits 100% 0% U
  Imaging tests frequency 4% 96% SC
  Analytic testing 84% 16% SC
  Additional blood pressure monitoring 80% 20% SC
 If you answered yes, which is your preferred choice of action during the first 3 months of enzalutamide therapy:
1/2 weeks Monthly Quarterly
  Frequent follow-up visits 4% 80% 16% SC
  Imaging tests frequency 14% 84% 12% SC
  Analytic testing 10% 70% 20% MC
 If you answered yes, which is your preferred choice of action during the first 3 months of abiraterone therapy:
1/2 weeks Monthly Quarterly
  Frequent follow-up visits 92% 8% 0% SC
  Analytic testing 84% 16% 0% SC
  Additional blood pressure monitoring 85% 15% 0% SC
 In an asymptomatic/minimally symptomatic M1 CPRC patient, follow-up tests must be performed:
  Every 3–6 months, regardless of PSA values 88% 12% SC
  When the PSA values double 96% 4% SC
  In the event of symptoms related to the metastatic disease appearing 100% 0% U
 In a symptomatic M1 CPRC patient, follow-up tests must be performed:
  Every 3 months, regardless of PSA values 84% 16% SC
  Every 6 months, regardless of PSA values 4% 96% SC
  When the PSA values double 96% 4% SC
  In the event of new symptoms appearing 100% 0% U
Values in bold indicate the consensus
U unanimity, SC strong consensus, MC moderate consensus, NC no consensus, CRPC castration-resistant prostate cancer, PSA prostate-specific 
antigen, NSAID non-steroidal anti-inflammatory drugs, BPI-SF short form of the Brief Pain Inventory questionnaire, PSA-DT prostate-specific 
antigen doubling-time, MRI magnetic resonance imaging, BS bone Scan, PET/CT positron emission tomography/computed tomography, LHRH 
luteinizing hormone-releasing hormone, LDH lactate dehydrogenase, AR androgen receptor, RT radiotherapy
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no detectable clinical metastases, baseline PSA level and 
PSA velocity/PSA doubling-time (DT) have been associated 
with the time to first bone metastasis, bone metastasis-free 
survival and overall survival [26, 27].
The RADAR group consensus [28] suggested that in 
asymptomatic men, a bone scan should be undertaken if PSA 
levels reached 2 ng/ml and, if negative, to undertake another 
bone scan if PSA reaches 5 ng/ml and every doubling of 
PSA level thereafter, based on PSA testing every 3 months.
The Prostate Cancer Working Group PCWG3 [22] recom-
mends that imaging should include cross-sectional imaging 
(chest, abdomen, pelvis), plus bone scintigraphy.
The emerging role of the next-generation imaging meth-
ods seems promising, despite a lack of systematically con-
ducted prospective studies. The prostate-specific membrane 
antigen (PSMA) PET can be considered as a highly promis-
ing tool in prostate cancer imaging due to higher detection 
rates, as compared with 11C-choline PET for lymph nodes 
as well as bone lesions, especially at low PSA levels [29]. 
Significantly, imaging strategies restricted to known sites 
of disease risk could miss disease progression at new sites. 
The NCCN (National Comprehensive Cancer Network) [30] 
includes MRI and PET.
The panel strongly agreed that a bone scan (BS) should 
be requested at CRPC diagnosis, regardless of PSA level 
(agreement of 88%), with a PSA level of > 10 ng/ml and/or 
PSA-DT at < 6 months (agreement of 92%) and at the onset 
of bone pain (92%).
Similarly, it was strongly agreed that a CT scan should be 
performed at diagnosis, regardless of PSA levels (96%), with 
a PSA level of > 10 ng/ml and/or PSA-DT < 6 months (88%) 
and at the onset of metastatic related symptoms (96%).
With regard to the use of choline PET/CT and whole-
body MRI, there was a strong consensus that both tests were 
appropriate as a follow-up to inconclusive M1 test results 
(Choline PET/CT, 88%; whole-body MRI, unanimity). 
The panel also strongly agreed that choline PET/CT (96%) 
should be also performed in the event of a negative con-
ventional extension study (CT and BS) and aggressive PSA 
kinetics. Likewise, there was a strong consensus on whole-
body MRI (80%) being performed in this situation.
The definition of oligometastasis has evolved over time. 
Originally defined as five or less metastatic sites [31], it has 
been proposed as a clinically significant state separate from 
the polymetastatic disease [32], with a better prognosis and 
survival rates compared with patients with extensive meta-
static disease [31, 32]. Significantly, aggressive local ther-
apy [33] during this time could delay the need for systemic 
therapies and/or prolong progression-free survival. Recent 
data show that in men with PSA-recurrent prostate cancer, a 
prolonged metastasis-free survival is significantly associated 
with a longer overall survival [34]. The St Gallen consensus 
2017 debated whether to propose a new clinical entity, the 
oligo-progressive mCRPC, but no agreement was reached 
on this issue [35].
The panel reached a strong consensus that the oligometa-
static CRPC patient is defined as having lymph node and/
or bone disease (5 or fewer sites) (92%). There was also a 
strong consensus that CT and BS (84%), choline PET/CT 
(88%) and whole-body MRI (80%) should be used as diag-
nostic tools for these patients. Finally, there was a strong 
consensus (96%) that choline PET/TC is not useful to iden-
tify oligometastasis in patients with a low PSA level (≤ 1 ng/
ml).
Topic 4—CRPC progression
The definition of CRPC progression is another cause for 
controversy and has varied over time. In many studies it has 
been considered as a rise in PSA levels following castration 
[3]. However, PSA alone is not reliable enough for moni-
toring disease activity in advanced CRPC because visceral 
metastases may develop in men without rising PSA [36]. 
Instead, the PCWG2 recommends a combination of bone 
scintigraphy and CT scans, PSA measurements, and clinical 
benefit in assessing men with CRPC. The PGW3 panel [22] 
and St. Gallen 2015 [17] stressed that agents with a proven 
overall survival benefit should not be stopped due to PSA 
progression alone. Moreover, at least two of three criteria 
(PSA progression, radiographic progression and clinical 
deterioration) should be fulfilled before stopping treatment.
In addition, the European expert panel consensus [15] 
defines primary resistance to AR pathway-targeted agents 
as a radiological progression within 3 months following 
therapy initiation, while a limited decrease in PSA level or 
progression within 3 months of therapy initiation was not 
sufficient for the diagnosis.
While short response to initial hormonal therapy seems 
to be associated with poor response to subsequent hormonal 
therapies, this is not always an indicator of absolute andro-
gen independence and does not exclude any potential benefit 
from novel AR-targeting strategies [15], such as abirater-
one or enzalutamide, which have demonstrated a positive 
outcome in overall survival and improvement in quality of 
life [7, 9].
There was a strong consensus that radiological (96%) and 
clinical progression (pain, overall status) (88%) had to be 
present in order to define disease progression. In contrast, 
the panel voted against an exclusive biochemical progression 
criteria in the definition (88%).
In addition, the experts strongly agreed that primary 
resistance to enzalutamide/abiraterone is defined as radio-
logical progression within 3–4 months of therapy initiation 
(92%), while an abscense of decline in PSA level (≥ 30%) 
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within 3 months does not serve to identify primary resistance 
(88%). There was no consensus on whether sustained PSA 
progression within 3–4 months of therapy initiation must 
be present in order to define resistance to these therapies.
Even though there is no complete agreement on a precise 
definition of a flare occurrence, there is a broad consensus 
that it is characterised by a rise in the PSA level, followed 
by a decline below baseline values after initiating different 
therapies [37, 38]. A bone scan flare has been also described 
by the NCCN [39] and must be clearly differentiated from 
“disease progression”. The PCWG3 suggests the use of 
the 2 + 2 rule to distinguish flare from true progression in 
patients with osseous disease at baseline.
A transient rise in PSA levels at therapy initiation has 
been described in patients receiving taxanes and abirater-
one [15, 39]. In a phase II study in mCRPC treated with 
abiraterone [39], bone scan flare was observed in a large 
proportion of patients (30% of the total and 44% of those 
who experienced a ≥ 5 0% decline in PSA), suggesting that 
more investigation is needed to clarify the potentially con-
founding effect of the bone scan flare phenomena. This flare 
phenomenon precedes actual response to treatment and can 
be misinterpreted as therapeutic failure, leading to prema-
ture discontinuation of potentially effective agents. While 
different studies have shown a flare occurrence after abira-
terone treatment [35, 40, 41], no such phenomena have been 
observed with enzalutamide [42].
The panel reached a strong consensus that a flare is 
defined as a temporary clinical and/or biochemical worsen-
ing of therapy initiation (92%). They unanimously agreed 
that flares occur following taxane and abiraterone treat-
ment. There was no consensus on the possible flare effect 
of enzalutamide.
Topic 5—M0 management
There is a lack of information in current clinical practice 
guidelines on which imaging modality should be used for 
M0 patients. It is crucial to consider the potential impact 
on survival in an early identification of asymptomatic M1. 
The ENTHUSE M0 trial found a high frequency of asymp-
tomatic metastasis (32%) in patients thought to have M0 
CRPC, highlighting the urgent need to improve imaging 
strategies for metastatic disease [43, 44]. Recommendations 
on when to initiate and repeat imaging in M0 CRPC patients 
have been published by the RADAR group [28].
The panel voted on the M0 definition criteria proposed 
by the RADAR group and they strongly agreed that in an 
M0 CRPC a baseline bone scan is required for a PSA level 
of ≥ 2 ng/ml (84%). The experts reached a strong consensus 
that a repeat bone scan should be performed if the PSA level 
rises to 5 ng/ml after the negative initial bone scan (88%). 
They also strongly agreed that for PSA levels of ≥ 5 ng/ml 
and a negative bone scan, the test should be repeated every 
doubling of PSA level thereafter based on PSA testing every 
3 months (88%).
The St Gallen 2015 [17] recommendation for men with 
M0 CRPC was to continue with ADT and add the older 
endocrine manipulations without proven survival benefit 
while acknowledging the lack of evidence about the ben-
efits of abiraterone or enzalutamide, while different stud-
ies support the use of palliative radiotherapy in this clinical 
situation.
The panel unanimously agreed that first-line treatment 
in an M0 CRPC patient with local clinical progression was 
radiotherapy (if there had been no previous radiotherapy) 
or salvage surgery. They also unanimously agreed that doc-
etaxel, abiraterone or enzalutamide should not be adminis-
tered in these cases until evidence from the ongoing rand-
omized clinical trials becomes available.
Even though the results on the benefits of the new antian-
drogens were not known when the different phases of the 
consensus were underway, the results of two phase III stud-
ies have confirmed the benefits of enzalutamide (PROSPER) 
and apalutamide (SPARTAN) in M0 CRPC patients and 
PSA doubling time < 10 months [45, 46]. Both drugs have 
constistently improved progression free survival compared 
with placebo, as well as metastasis free survival.
Topic 6—M1 management and sequencing therapy
Asymptomatic/minimally symptomatic M1 CRPC 
patient More than 84% of patients have metastases at CRPC 
diagnosis. In those without metastases at diagnosis, 33% of 
patients with CRPC develop metastases within 2 years of 
their diagnosis [6, 7, 47]. The new androgen-receptor inhib-
itors which demonstrates efficacy in the metastatic CRPC 
setting have changed the paradigm of CRPC treatment [28]. 
Abiraterone and enzalutamide have been evaluated as first-
line agents in asymptomatic patients [48, 49] and are recom-
mended as first-line therapy in the ESMO [50] and SEOM 
[3] Clinical Practice Guidelines.
The St Gallen consensus (2015, 2017) [17, 35] agreed 
that asymptomatic men with mCRPC should receive abira-
terone or enzalutamide as first-line treatment, independently 
of whether they had received ADT alone or ADT plus doc-
etaxel in the castration-naïve setting [16, 34]. Similarly, the 
EAU-ESTRO-SIOG guidelines [25] proposed different ther-
apies, including abiraterone, enzalutamide, sipuleucel-T and 
docetaxel, and the URONCOR consensus statement includes 
sipuleucel-T and abiraterone acetate plus prednisone [21].
Visceral metastases are nowadays more commonly 
detected [36] and autopsy studies on men who died from 
prostate cancer suggested a higher prevalence of visceral 
metastases in up to 66% of selected cases [51]. Even though 
this population has a poor prognosis and are frequently 
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excluded from other trials, research with new survival-
prolonging treatments has changed this paradigm. In the 
PREVAIL study, enzalutamide treatment showed a consist-
ent benefit in some patients with visceral metastatic disease 
[52].
The panel unanimously voted that most asymptomatic/
minimally symptomatic M1 CRPC patients should receive 
abiraterone or enzalutamide as first-line treatment while doc-
etaxel should only be used in some aggressive cases. They 
unanimously voted not to use docetaxel as a first option in 
many cases.
In an asymptomatic/minimally symptomatic M1 CRPC 
patient with visceral metastases, the panel strongly agreed 
(80%) to consider enzalutamide as first-line treatment. 
They voted unanimously not to consider abiraterone as 
first-line treatment and reached a strong consensus on not 
recommending docetaxel as first-line therapy (80%).
In accordance with the results of COU-32 [53] and 
PREVAIL [52], the NCCN [30] considers that enzalu-
tamide treatment should be monitored for fatigue, diar-
rhoea, hot flashes and seizures (reported in 0.9% of men 
on enzalutamide). The side effects of abiraterone require 
monitoring for hypertension, hypokalaemia, peripheral 
oedema, atrial fibrillation, congestive heart failure, liver 
injury and fatigue.
The panel strongly agreed that the choice of treatment for 
these patients would be influenced by the following factors: 
visceral metastases (96%), cardiovascular history (72%), 
prior seizures (80%) and steroid contraindications (96%). 
Only half of them considered that hypertension would have 
an influence on their decision.
Finally, there was a strong consensus (88%) that second-
ary hormonal manipulations are suitable for patients who are 
not candidates for chemotherapy, regardless of enzalutamide 
or abiraterone availability.
Symptomatic M1 CRPC patient The EAU-ESTRO-SIOG 
guidelines [25] suggest that symptomatic M1 CRPC 
patients should receive docetaxel as first-line therapy and 
radium-223 if they have bone/non-visceral metastasis. The 
second-line choice would include enzalutamide, abirater-
one, docetaxel, cabazitaxel or radium-223, depending on 
previous therapy. The SEOM guidelines [3] also suggest 
that abiraterone or enzalutamide are an alternative first-line 
treatment for symptomatic mCRPC patients who are doc-
etaxel-naïve or unfit or unwilling to receive docetaxel.
The panel strong agreed that the first-line therapy for 
symptomatic M1 CRPC should be docetaxel (84%) and 
radium-223 in patients with bone metastases (non-visceral) 
(92%), but they did not consider that enzalutamide/abirater-
one should be recommended (84%).
There was a strong consensus that most CRPC patients 
with symptomatic bone metastasis should receive 
bone-targeting therapies (bisphosphonates, denosumab) 
(88%) until the onset of the bone progression (82%).
Oligometastatic M1 CRPC patient Interest has increased 
in the potential role of definitive metastasis-directed ther-
apy for men with oligometastatic disease, defined as few 
(often ≤ 5) metastatic lesions, even in the absence of symp-
toms [33]. It has been proposed as a distinct clinical entity 
from metastasis, considered to be an intermediate state of 
tumour spread with limited metastatic capacity [32, 33].
In CRPC patients, the management of men with oligo-
metastatic disease is another area where trial data is lacking, 
making it an important research question [35].
The panel strongly agreed that local control of oligome-
tastasis decreases symptoms (92%), delays the start of a new 
systemic therapy (88%) and could increase overall survival 
and/or progression-free survival (84%).
In the CPRC oligometastatic patient, local ablative ther-
apy in addition to enzalutamide/abiraterone must be con-
sidered (92%) and it was unanimously agreed that a radical 
prostate treatment should be also considered.
Topic 7—treatment monitoring
Even though it is generally accepted that regular treatment 
response monitoring should be undertaken, there are no 
agreed guidelines on the precise clinical, laboratory and 
imaging evaluations or on the frequency of scheduling fol-
low-up visits.
According to the EAU-ESTRO-SIOG guidelines, moni-
toring M1 CPRC treatment should include a physical exami-
nation, baseline blood tests, a whole-body CT scan and a 
bone scan every 6 months.
The NCCN [30] recommend that in M1 patients there 
must be a physical examination and PSA levels tested every 
3–6 months, with a bone scan taken every 6–12 months.
According to the PCWG3 [22], analytical tests should 
be performed every 3–4 weeks and image tests taken at 
8- or 9-week-intervals in case there is a flare occurrence. 
The URONCOR consensus [21] recommended that patient 
should be monitored 1 month after initiation therapy and 
that radiological imaging should be done every 3 months.
Finally, the European consensus of 2014 [14] recom-
mends early imaging at 3 months to detect any resistance 
to new agents.
There was a strong consensus that a Tc-99 m bone scan 
(84%), a whole-body MRI and/or axial skeleton (92%), and 
a Choline PET/TC (84%) were all suitable to evaluate bone 
metastasis response to the therapy.
The panel unanimously agreed (100%) that in asymp-
tomatic/minimally symptomatic men with M1 CRPC, the 
choice of first-line therapy influences the frequency of fol-
low-up patient visits, blood tests (84%) and blood pressure 
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monitoring (80%). Conversely, they strongly agreed that the 
frequency of imaging tests was not influenced by the first-
line therapy choice (96%).
The panel also strongly agreed that during the first 
3 months of enzalutamide therapy the frequency of patient 
visits (80%), blood tests (84%) and blood pressure monitor-
ing (70%) should be done every month.
During the first 3 months of abiraterone therapy, there 
was also a strong consensus that the frequency of patient 
visits (80%), blood tests (84%) and additional blood pressure 
monitoring (70%) should be undertaken every 1–2 weeks.
In an asymptomatic/minimally symptomatic M1 CPRC 
patient, the panel strongly agreed that follow-up tests must 
be scheduled either every 3-6 months regardless of PSA val-
ues (88%) or, when PSA levels double (96%), and they unan-
imously agreed that follow-up tests should be performed if 
symptoms related to the metastatic disease appeared (100%).
In an M1 CPRC symptomatic patient, the panel strongly 
agreed that follow-up tests must be scheduled either every 
3 months regardless of PSA values (84%) or when PSA lev-
els double (96%). They unanimously agreed that follow-up 
tests should be performed if new symptoms appeared (100%) 
but they strongly agreed that 6 months was too infrequent, 
regardless of PSA values (96%).
Conclusion
The present consensus document is intended to be a useful 
tool, providing radiation oncology specialists with expert 
guidance on and standards for CRPC patient management 
in Spain. It provides 116 statements that have been agreed 
following a modified Delphi method. A strong consensus 
or unanimity has been reached on 108 out of the 116 (93%) 
questions. This is especially important considering that 
CRPC management is still challenging due to the hetero-
geneity of the disease, the high number of different thera-
peutic options available, the lack of head-to-head clinical 
trials, primary or acquired resistance, and the incidence of 
metastatic progression. In addition to these guidelines the 
clinical judgement and experience of the treating physician 
in clinical practice is also required in the decision-making 
process for each of the different clinically relevant areas for 
CRPC patients.
Acknowledgements The authors want to express their gratitude to 
Astellas Pharma for the financial support provided to carry out this 
Delphi method consensus and to GOC Networking for their contribu-
tion with the methodology used and medical writing support.
Cabeza Rodríguez M.A.; Hospital Universitario 12 de Octubre 
Madrid, Celada Álvarez F.; Hospital La Fe Valencia, Ferrer Albiach 
C.; Consorcio Hospitalario Provincial Castellón, Ferrer González F.; 
Hospital Duran y Reynals Barcelona, Gómez-Iturriaga A.; Hospital de 
Cruces Vizcaya, Guerrero Grande A.; Hospital Son Espases Palma de 
Mallorca, Herruzo Cabrera I.; Hospital Carlos Haya Málaga, Hervás 
Morón A.; Hospital Ramón y Cajal Madrid, López-Torrecilla J.; Hospi-
tal General Universitario- ERESA Valencia, Lozano Martínez A.; Hos-
pital Universitario Virgen de la Arrixaca Murcia, Macías Hernández 
V.; Hospital Universitario Salamanca, Mira Flores M.; Hospital Arnau 
de Vilanova LLeida, Morera López R.; Hospital La Paz Madrid, Muñoz 
García J.; Hospital Infanta Cristina Badajoz, Olivera Vegas J.; Hospital 
Universitario Fundación Jiménez Díaz Madrid, Palacios Eito A.; Hos-
pital Reina Sofía Córdoba, Rodríguez Melcón I.; Hospital Dr. Negrín 
Gran Canaria, Salinas Ramos J.; Hospital Santa Lucía de Cartagena 
Murcia, Samper Ots P.; Hospital Universitario Rey Juan Carlos Madrid, 
Sancho Pardo G.; Hospital de la Santa Creu i Sant Pau Barcelona.
Compliance with ethical standards 
Conflict of interest The authors declare no conflict of interest in this 
article.
Research involving human participants and/or animals Not applicable.
Informed consent Not applicable.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Galceran J, Ameijide A, Carulla M, Mateos A, Quiros JR, Rojas 
D, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol. 
2017;19(7):799–825.
 2. Rodriguez A, Borras JM, Lopez-Torrecilla J, Algara M, Palacios-
Eito A, Gomez-Caamano A, et al. Demand for radiotherapy in 
Spain. Clin Transl Oncol. 2017;19(2):204–10.
 3. Cassinello J, Arranz JA, Piulats JM, Sanchez A, Perez-Valderrama 
B, Mellado B, et al. SEOM clinical guidelines for the treatment of 
metastatic prostate cancer. Clin Transl Oncol. 2018;20(1):57–68.
 4. Chirlaque MD, Salmeron D, Galceran J, Ameijide A, Mateos 
A, Torrella A, et al. Cancer survival in adult patients in Spain. 
Results from nine population-based cancer registries. Clin Transl 
Oncol. 2018;20(2):201–11.
 5. Campa J, Mar-Barrutia G, Extramiana J, Arrospide A, Mar J. 
Advanced prostate cancer survival in Spain according to the Glea-
son score, age and stage. Actas Urol Esp. 2016;40(8):499–506.
 6. Kirby M, Hirst C, Crawford ED. Characterising the castration-
resistant prostate cancer population: a systematic review. Int J 
Clin Pract. 2011;65(11):1180–92.
 7. Inoue T, Segawa T, Kamba T, Yoshimura K, Nakamura E, Nishiy-
ama H, et al. Prevalence of skeletal complications and their impact 
on survival of hormone refractory prostate cancer patients in 
Japan. Urology. 2009;73(5):1104–9.
 8. Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med. 
2018;378(7):645–57.
 9. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, 
et al. Increased survival with enzalutamide in prostate cancer after 
chemotherapy. N Engl J Med. 2012;367(13):1187–97.
 10. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, 
et al. Abiraterone and increased survival in metastatic prostate 
cancer. N Engl J Med. 2011;364(21):1995–2005.
431Clinical and Translational Oncology (2019) 21:420–432 
1 3
 11. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Pen-
son DF, et al. Sipuleucel-T immunotherapy for castration-resistant 
prostate cancer. N Engl J Med. 2010;363(5):411–22.
 12. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa 
SD, et al. Alpha emitter radium-223 and survival in metastatic 
prostate cancer. N Engl J Med. 2013;369(3):213–23.
 13. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, 
Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for 
metastatic castration-resistant prostate cancer progressing after 
docetaxel treatment: a randomised open-label trial. Lancet. 
2010;376(9747):1147–54.
 14. Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff 
PW. Current treatment strategies for advanced prostate cancer. Int 
J Urol. 2018;25(3):220–31.
 15. Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg 
CN, Tombal B, et al. Optimal management of metastatic castra-
tion-resistant prostate cancer: highlights from a European Expert 
Consensus Panel. Eur J Cancer. 2014;50(9):1617–27.
 16. Alcaraz A, Martinez-Pineiro L, Rodriguez A, Rubio J, Borque A, 
Burgos J, et al. Consensus on castration-resistant prostate cancer 
management in Spain. Arch Esp Urol. 2017;70(9):777–91.
 17. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, 
Fizazi K, et al. Management of patients with advanced prostate 
cancer: recommendations of the St Gallen Advanced Prostate 
Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 
2015;26(8):1589–604.
 18. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, 
Tannock I, de Wit R, et al. Prostate-specific antigen and pain sur-
rogacy analysis in metastatic hormone-refractory prostate cancer. 
J Clin Oncol. 2007;25(25):3965–70.
 19. Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal 
N, et al. Randomized, double-blind, placebo-controlled phase III 
study of tasquinimod in men with metastatic castration-resistant 
prostate cancer. J Clin Oncol. 2016;34(22):2636–43.
 20. Jadad AR, Browman GP. The WHO analgesic ladder for can-
cer pain management. Stepping up the quality of its evaluation. 
JAMA. 1995;274(23):1870–3.
 21. Lopez Torrecilla J, Hervas A, Zapatero A, Gomez Caamano A, 
Macias V, Herruzo I, et al. Uroncor consensus statement: man-
agement of biochemical recurrence after radical radiotherapy for 
prostate cancer: From biochemical failure to castration resistance. 
Rep Pract Oncol Radiother. 2015;20(4):259–72.
 22. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, 
et al. Trial design and objectives for castration-resistant prostate 
cancer: updated recommendations from the prostate cancer clini-
cal trials working group 3. J Clin Oncol. 2016;34(12):1402–18.
 23. Ferrer M, Guedea F, Suárez JF, de Paula B, Macías V, Mariño A, 
et al. Quality of life impact of treatments for localized prostate 
cancer: cohort study with a 5 year follow-up. Radiother Oncol. 
2013;108(2):306–13.
 24. Malcolm JB, Fabrizio MD, Barone BB, Given RW, Lance RS, 
Lynch DF, et al. Quality of life after open or robotic prostatec-
tomy, cryoablation or brachytherapy for localized prostate cancer. 
J Urol. 2010;183(5):1822–8.
 25. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, 
EAU-ESTRO-SIOG Guidelines on Prostate Cancer, et al. Part II: 
treatment of relapsing, metastatic, and castration-resistant prostate 
cancer. Eur Urol. 2017;71(4):630–42.
 26. Smith MR, Cook R, Lee KA, Nelson JB. Disease and host charac-
teristics as predictors of time to first bone metastasis and death in 
men with progressive castration-resistant nonmetastatic prostate 
cancer. Cancer. 2011;117(10):2077–85.
 27. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, 
Bilhartz DL, et al. Natural history of rising serum prostate-specific 
antigen in men with castrate nonmetastatic prostate cancer. J Clin 
Oncol. 2005;23(13):2918–25.
 28. Crawford ED, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, 
et al. Challenges and recommendations for early identification of 
metastatic disease in prostate cancer. Urology. 2014;83(3):664–9.
 29. Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, 
et al. Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline 
in the detection of prostate cancer metastases by PET/CT. Eur J 
Nucl Med Mol Imaging. 2017;44(1):92–101.
 30. NCCN clinical practice guidelines in prostate cancer, Version 
2.2017, February 21, 2017. https ://www.nccn.org/profe ssion als/
physi cian_gls/pdf/prost ate.pdf. Accessed 21 Feb 2017.
 31. Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams 
JP, et al. Is there a favorable subset of patients with prostate can-
cer who develop oligometastases? Int J Radiat Oncol Biol Phys. 
2004;58(1):3–10.
 32. Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, 
Karnes RJ, et al. Metastasis-directed therapy of regional and 
distant recurrences after curative treatment of prostate cancer: a 
systematic review of the literature. Eur Urol. 2015;67(5):852–63.
 33. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev 
Clin Oncol. 2011;8(6):378–82.
 34. Schweizer MT, Zhou XC, Wang H, Yang T, Shaukat F, Partin AW, 
et al. Metastasis-free survival is associated with overall survival 
in men with PSA-recurrent prostate cancer treated with deferred 
androgen deprivation therapy. Ann Oncol. 2013;24(11):2881–6.
 35. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow 
R, et al. Management of patients with advanced prostate cancer: 
the report of the advanced prostate cancer consensus conference 
APCCC 2017. Eur Urol. 2018;73(2):178–211.
 36. Pezaro C, Omlin A, Lorente D, Rodrigues DN, Ferraldeschi R, 
Bianchini D, et al. Visceral disease in castration-resistant prostate 
cancer. Eur Urol. 2014;65(2):270–3.
 37. Narmala SK, Boulmay BC. PSA flare after initiation of abirater-
one acetate. J Commun Support Oncol. 2014;12(5):191–2.
 38. Thuret R, Massard C, Gross-Goupil M, Escudier B, Di Palma M, 
Bossi A, et al. The postchemotherapy PSA surge syndrome. Ann 
Oncol. 2008;19(7):1308–11.
 39. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley 
GJ, et al. Phase II study of abiraterone acetate in chemotherapy-
naive metastatic castration-resistant prostate cancer displaying 
bone flare discordant with serologic response. Clin Cancer Res. 
2011;17(14):4854–61.
 40. Burgio SL, Conteduca V, Rudnas B, Carrozza F, Campadelli E, 
Bianchi E, et al. PSA flare with abiraterone in patients with meta-
static castration-resistant prostate cancer. Clin Genitourin Cancer. 
2015;13(1):39–43.
 41. Ueda Y, Matsubara N, Tabata KI, Satoh T, Kamiya N, Suzuki 
H, et al. Prostate-specific antigen flare phenomenon induced by 
abiraterone acetate in chemotherapy-naive patients with meta-
static castration-resistant prostate cancer. Clin Genitourin Cancer. 
2017;15(2):320–5.
 42. Armstrong AJ, Saad F, Phung Dmuchowski C, Shore ND, Fizazi 
K, et al. Clinical outcomes and survival surrogacy studies of pros-
tate-specific antigen declines following enzalutamide in men with 
metastatic castration-resistant prostate cancer previously treated 
with docetaxel. Cancer. 2017;123(12):2303–11.
 43. Yu EY, Miller K, Nelson J, Gleave M, Fizazi K, Moul JW, et al. 
Detection of previously unidentified metastatic disease as a lead-
ing cause of screening failure in a phase III trial of zibotentan 
versus placebo in patients with nonmetastatic, castration resistant 
prostate cancer. J Urol. 2012;188(1):103–9.
 44. White R, Khor R, Bressel M, Duchesne G, Williams S, Bowden 
P, et al. Efficacy of high-dose palliative radiotherapy for localised, 
castration-resistant prostate cancer. Clin Oncol (R Coll Radiol). 
2015;27(1):16–21.
 45. Hussain M, Fizazi K, Saad F, Rathenborg P, Shore ND, Demirhan 
E, et al. PROSPER: A phase 3, randomized, double-blind, placebo 
432 Clinical and Translational Oncology (2019) 21:420–432
1 3
(PBO)-controlled study of enzalutamide (ENZA) in men with 
nonmetastatic castration-resistant prostate cancer (M0 CRPC). J 
Clin Oncol. 2018;36:6_suppl, 3-3.
 46. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff 
JN, et al. Apalutamide treatment and metastasis-free survival in 
prostate cancer. N Engl J Med. 2018;378(15):1408–18.
 47. Berruti A, Tucci M, Mosca A, Tarabuzzi R, Gorzegno G, Terrone 
C, et al. Predictive factors for skeletal complications in hormone-
refractory prostate cancer patients with metastatic bone disease. 
Br J Cancer. 2005;93(6):633–8.
 48. Ryan CJ, Molina A, Griffin T. Abiraterone in metastatic prostate 
cancer. N Engl J Med. 2018;378(15):1408–18.
 49. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, 
Higano CS, et al. Enzalutamide in metastatic prostate cancer 
before chemotherapy. N Engl J Med. 2014;371(5):424–33.
 50. Parker C, Gillessen S, Heidenreich A, Horwich A. Cancer of the 
prostate: ESMO Clinical Practice Guidelines for diagnosis, treat-
ment and follow-up. Ann Oncol. 2015;26(Suppl 5):v69–77.
 51. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, 
et al. Androgen-independent prostate cancer is a heterogeneous 
group of diseases: lessons from a rapid autopsy program. Cancer 
Res. 2004;64(24):9209–16.
 52. Evans CP, Higano CS, Keane T, Andriole G, Saad F, Iversen P, 
et al. The PREVAIL Study: primary outcomes by site and extent 
of baseline disease for enzalutamide-treated men with chemother-
apy-naïve metastatic castration-resistant prostate cancer. Eur Urol. 
2016;70(4):675–83.
 53. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg 
CN, et al. Abiraterone acetate plus prednisone versus placebo plus 
prednisone in chemotherapy-naive men with metastatic castration-
resistant prostate cancer (COU-AA-302): final overall survival 
analysis of a randomised, double-blind, placebo-controlled phase 
3 study. Lancet Oncol. 2015;16(2):152–60.
